GlassScriptPhysician profile
Karen Jackson
NPI 1205330065
$2,486.35
in general payments reported to CMS, 2019-2025
16 companies · $637 in 2025
The $637 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $217 · 2023: $560 · 2024: $1,072 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,268.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $569.09 | 2023-2025 | Invega Sustenna, Invega Trinza |
| Neurocrine Biosciences, INC. | $249.38 | 2024-2025 | Ingrezza |
| Abbvie INC. | $223.09 | 2023-2024 | |
| Argenx US, INC. | $131.71 | 2023 | Vyvgart |
| Jazz Pharmaceuticals INC. | $129.31 | 2022 | |
| Abbott Laboratories | $125.30 | 2023 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $124.99 | 2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $124.86 | 2024 | Quviviq |
| Genzyme Corporation | $124.80 | 2024 | |
| Gilead Sciences, INC. | $124.26 | 2024 | Epclusa |
| Teva Pharmaceuticals USA, INC. | $121.83 | 2025 | Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $116.54 | 2024 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $107.11 | 2024 | Caplyta |
| Vanda Pharmaceuticals INC. | $101.26 | 2025 | Fanapt |
| Cvrx, INC. | $88.10 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $24.72 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.